Results 151 to 160 of about 240,433 (353)
Table S2 from MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by <i>TP53</i> Mutation in Preclinical Models of Colorectal Cancer
, 2023 Celina García-García, Martín A. Rivas, Yasir H. Ibrahim, María Teresa Calvo, Albert Gris‐Oliver, Olga Rodríguez, Judit Grueso, Pilar Antón, Marta Guzmán, Claudia Aura, Paolo Nucíforo, Katti Jessen, Guillem Argilés, Rodrigo Dienstmann, Andrea Bertotti, Livio Trusolino, Judit Matito, Ana Vivancos, Irene Chicote, Héctor G. Pálmer, Josep Tabernero, Maurizio Scaltriti, José Baselga, Violeta Serra +23 moreopenalex +1 more sourceClinically Informed Intelligent Classification of Ovarian Cancer Cells by Label‐Free Holographic Imaging Flow Cytometry
Advanced Intelligent Systems, Volume 7, Issue 3, March 2025.Quantitative phase maps of single cells recorded in flow cytometry modality feed a hierarchical architecture of machine learning models for the label‐free identification of subtypes of ovarian cancer. The employment of a priori clinical information improves the classification performance, thus emulating the clinical application of liquid biopsy during ...Daniele Pirone, Beatrice Cavina, Daniele Gaetano Sirico, Martina Mugnano, Vittorio Bianco, Lisa Miccio, Anna Myriam Perrone, Anna Maria Porcelli, Giuseppe Gasparre, Ivana Kurelac, Pasquale Memmolo, Pietro Ferraro +11 morewiley +1 more sourceData from Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in <i>TP53</i>-Mutant Cancers
, 2023 Jeffrey Patterson-Fortin, Arindam Bose, Wei-Chih Tsai, Carter Grochala, Huy Nguyen, Jia Zhou, Kalindi Parmar, Jean‐Bernard Lazaro, Joyce F. Liu, Kelsey McQueen, Geoffrey I. Shapiro, David Kozono, Alan D. D’Andrea +12 moreopenalex +1 more sourceNavigating the Post‐BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis
American Journal of Hematology, EarlyView.ABSTRACT
Patients with relapsed/refractory multiple myeloma (RRMM) who are penta‐drug refractory, defined as resistant to two proteasome inhibitors, two immunomodulatory agents, and an anti‐CD38 monoclonal antibody, face a dismal prognosis, particularly after exposure to T‐cell–redirecting therapies.Maximilian Al‐Bazaz, Winfried Alsdorf, Lisa Leypoldt, Piet Sonnemann, Christoph Schaefers, Jule Artzenroth, Marie Harzer, Abdulaziz Kamili, Leandra Bartke, Leon Cords, Jan Vorwerk, Theo Leitner, Markus Maulhardt, Kerstin Brinkert, Annamaria Brioli, Tim Richardson, Udo Holtick, Stefan M. Hillmann, Hans Salwender, Cyrus Khandanpour, Carsten Bokemeyer, Katja Weisel, Ricardo Kosch +22 morewiley +1 more sourceSupplementary Figure 3 from Evolutionary Action Score of <i>TP53</i> Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients
, 2023 Abdullah A. Osman, David M. Neskey, Panagiotis Katsonis, Ameeta A. Patel, Alexandra M. Ward, Teng‐Kuei Hsu, Stephanie C. Hicks, Thomas O. McDonald, Thomas J. Ow, Marcus Ortega Alves, Curtis R. Pickering, Heath D. Skinner, Mei Zhao, Eric M. Sturgis, Merrill S. Kies, Adel K. El‐Naggar, Federica Perrone, Lisa Licitra, Paolo Bossi, Marek Kimmel, Mitchell J. Frederick, Olivier Lichtarge, Jeffrey N. Myers +22 moreopenalex +1 more sourceSupplementary Table 2 from Evolutionary Action Score of <i>TP53</i> Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients
, 2023 Abdullah A. Osman, David M. Neskey, Panagiotis Katsonis, Ameeta A. Patel, Alexandra M. Ward, Teng‐Kuei Hsu, Stephanie C. Hicks, Thomas O. McDonald, Thomas J. Ow, Marcus Ortega Alves, Curtis R. Pickering, Heath D. Skinner, Mei Zhao, Eric M. Sturgis, Merrill S. Kies, Adel K. El‐Naggar, Federica Perrone, Lisa Licitra, Paolo Bossi, Marek Kimmel, Mitchell J. Frederick, Olivier Lichtarge, Jeffrey N. Myers +22 moreopenalex +1 more source
